SLC30A6 (ZnT6) is a zinc transporter that lacks intrinsic transporter activity independently but functions as a key component of a heterodimeric zinc:proton antiporter complex with SLC30A5, mediating zinc entry into organelles along the secretory pathway 123. This heterodimer regulates zinc homeostasis within the early secretory pathway and supports activation and folding of enzymes including alkaline phosphatases and those involved in phosphatidylinositol glycan anchor biosynthesis 134. SLC30A6 is upregulated in colorectal cancer tissues and localizes to endoplasmic reticulum membranes as part of a coordinated transcriptional program associated with increased early secretory pathway activity 5. In pancreatic ductal adenocarcinoma, elevated SLC30A6 expression correlates with poor prognosis (HR=1.90, p=0.003) and is involved in epithelial-mesenchymal transition, TNF-α signaling, and angiogenesis pathways 6. SLC30A6 has been identified as a genetic target in chr2 back pain 7 and erectile dysfunction 8 through genome-wide and transcriptome-wide association studies. Cardiomyocyte overexpression of SLC30A6 induces mitochondrial dysfunction, altered epigenetic modifications, and impaired cardiac function 9.